Highest-materiality recent filing
Phibro Animal Health reports record FY2026 results, raises FY2027 guidance
Q4 net sales $396.7M (+5% YoY); diluted EPS $0.53 (+26%); adjusted EPS $0.85 (+35%).
Daniel Bendheim appointed CEO & President effective July 1, 2026; base salary $850k, target bonus 50% of salary.
Phibro Animal Health Q3 FY2026: Sales $383.5M (+10%), Adj. EBITDA $60.8M (+11%); Guidance raised
Q3 net sales $383.5M, +10% YoY; Animal Health segment +13% to $291.2M, driven by MFA portfolio, nutritional specialties, vaccines.
Phibro Animal Health expands revolving credit facility by $125M to $435M
Revolver increased from $310M to $435M via Amendment No. 1 dated April 28, 2026.
Phibro Q2 net sales up 21% to $374M; raises FY2026 guidance
Net sales $373.9M (+21% YoY); net income $27.5M vs $3.2M; diluted EPS $0.67 vs $0.08.
Jack C. Bendheim will resign as CEO and President effective July 1, 2026, and assume the new role of Executive Chairman.
Phibro Q1 net sales up 40% to $363.9M; raises FY2026 adjusted EBITDA guidance to $230-240M
Net sales $363.9M (+40% YoY); net income $26.5M ($0.65 diluted EPS) vs $7.0M ($0.17) prior year.
Phibro Animal Health Q4 net sales up 39% to $378.7M; FY2026 guidance sees 25% adj. EBITDA growth
Q4 net sales $378.7M (+39% YoY), net income $17.2M vs $0.8M, adj. diluted EPS $0.57 (+39%).
Phibro Animal Health Q3 net sales up 32% to $347.8M; Adj EBITDA +85%; raises FY2025 guidance
Q3 net sales $347.8M (+32% YoY); net income $20.9M (+$12.5M); diluted EPS $0.51 (+$0.30).
Phibro Q2 net sales up 24% to $309M; adjusted EPS $0.54 (+64% YoY); raises FY25 guidance
Net sales $309.3M (+24% YoY); Animal Health up 33% on Zoetis MFA acquisition added $36.7M.
Phibro discloses Zoetis MFA portfolio audited financials: $407.6M revenue in FY2023
Acquired MFA portfolio had $407.6M revenue & $91.2M revenue less direct expenses in 2023; up from $59.9M in 2022.
Phibro Q1 net sales $260.4M (+13% YoY), net income $7.0M vs loss; updates FY25 guidance
Net sales $260.4M (+13% YoY); net income $7.0M vs net loss $8.0M; diluted EPS $0.17 vs -$0.20.
Phibro completes $350M acquisition of Zoetis' medicated feed additive portfolio
Acquired >37 product lines across ~80 countries, six manufacturing sites in US, Italy, China, and >300 employees.
Phibro Q4 net sales up 7% to $273.2M; FY2025 guidance sees 10% adjusted EBITDA growth
Q4 GAAP net income of $0.8M ($0.02 EPS) vs $11.5M ($0.28 EPS) YoY; adjusted EPS $0.41 (+10%).
Phibro Animal Health enters $960M credit facility with Rabobank; delayed draw for Zoetis acquisition
Term A-1 loans total $351M (initial $162M + delayed $189M); Term A-2 loans total $299M.
Phibro Animal Health Reports Q3 FY2024 Results; Updates Guidance, Plans Zoetis Acquisition
Net sales for Q3 ended March 31, 2024 were $263.2M, up 7% YoY; Animal Health segment grew 10%.
Phibro Animal Health acquires Zoetis' medicated feed additive portfolio for $350M
$350M cash purchase; acquired portfolio generated ~$400M revenue in 2023 across 37 product lines.
Phibro reports Q2 diluted EPS of $0.03 on net income of $1.3M; reaffirms adjusted EBITDA guidance
Net sales $249.9M (+2% YoY); Animal Health segment up 6% led by 31% vaccine growth.
Phibro Animal Health appoints Glenn C. David as CFO effective Feb 9, 2024
Glenn C. David, former Zoetis CFO and group president, joins Phibro as CFO starting Feb 9, 2024.
Phibro Animal Health reports Q1 net loss of $8.0M; lowers FY2024 guidance
Net sales $231.3M (-1% YoY); net loss $8.0M vs $3.9M net income prior year; diluted loss per share $0.20.
Phibro Animal Health faces FDA actions to revoke Mecadox approval; $20M sales at risk
FDA issued final order revoking approved method for detecting carbadox residues in swine.
Phibro Q4 adj diluted EPS up 5% to $0.38; full-year net income down 34%
Q4 net sales $255.0M (flat YoY); net income $11.5M (+54%); adj diluted EPS $0.38 (+5%).
Phibro Animal Health enters $50M incremental term loan amendment to credit agreement
Incurred $50M incremental term loans on June 16, 2023 under amended credit agreement.
Phibro Q3 net income falls 43% to $10.0M; Animal Health sales up 11%
Q3 net sales $245.7M (+3% YoY); net income $10.0M (-43%); diluted EPS $0.25 (-43%); adjusted diluted EPS $0.29 (-13%).
Phibro Animal Health Q2 net income down 59% to $7.2M; guidance lowered on environmental costs
Net sales $244.6M (+5% YoY); GAAP diluted EPS $0.18 vs $0.43 prior; adjusted diluted EPS $0.34 vs $0.37.
Phibro Q1 net income down 41% to $3.9M; lowers FY2023 EPS guidance due to rates, tax
Q1 net sales $232.5M (+8% YoY); diluted EPS $0.10 (-41%); adjusted diluted EPS $0.21 (-18%).
On June 25, 2026, in connection with Daniel (Dani) Bendheim’s appointment to the role of Chief Executive Officer and President of the Company effective July 1, 2026
The Board of Directors (the “Board”) of Phibro Animal Health Corporation (the “Corporation”) appointed Joyce J. Lee as a Class II director of the Corporation, effective January 21, 2025.
On November 7, 2024, Phibro Animal Health Corporation (the “Company”) was notified by Rob Aukerman that he will be retiring from his position as President, North America Region of the Company effective December 31, 2024.
Todd Armstrong, currently serving as Vice President of the US Ruminant Business since 2020, will be promoted to President, North American Region, effective January 1, 2025.
Glenn C. David has joined Phibro and will assume the role of Chief Financial Officer effective February 9, 2024
Mr. Richard Johnson, who has served as Phibro’s interim Chief Financial Officer since September 29, 2023, will continue with Phibro for a period of time in an advisory capacity to ensure a smooth transition with Mr. David.
Damian Finio informed the Company that he will be resigning from his position as Chief Financial Officer of the Company effective September 29, 2023.
Richard G. Johnson, the former Chief Financial Officer of the Company, who has been serving as a Finance Advisor to the Company since November 16, 2020, will assume the role of interim Chief Financial Officer until a successor to Mr. Finio is identified.
appointed Alejandro Bernal as a Class III director of the Corporation, effective February 6, 2023.
Max materiality 0.90 · Median 0.60 · Most common event earnings